The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
How ever SS big mouth from BB days and now not even a drop of news and let SP dwindle this low, shows he not a competent person and should step down.
Qwerty59 100 tankers is not proof HH is kicking and live, its the shorters and market manipulators forcing hand of the SP, however when SS drops RNS lots be running to the hills, we seen clear evidence oil is flowing at HH.
I smell lots of oil just need the torch light now ignite the SP.
things going to get mighty interesting pump is full throttle today....
seen lot of 1m trades seem suspect to me....thats all,
looks like shorts closing buyers ready to move in....lets get decent close set up for tomorrow.
Zoom you might got lucky 1 code just gone through.
Could we go blue into close ?
1m full ask paid
has ss done a runner, left sinking ship,
tomorrow blame it on the wind or the sun, the fact this ceo been testing for 150 days and now let Sp slip 50% for 2p plus is a joke and he is not someone who you would want to running this company any one who is happy with this needs head examined.
wasred go do one sp dropping and its duty of the ceo to steady the ship one form or another not loose millions on the mcap daily.
well said Jrlomax best comment so far....what a knxx SS
pull your little finger out!!!
Well least its positive This analysis considers the clinical significance of the VAL401 results in comparison to previously reported data for conventional risperidone, providing a theoretical insight into the altered activity of the therapeutic
Results publication The peer-reviewed article will appear in the European Journal of Drug Metabolism and Pharmacokinetics early in 2019. The article details and analyses the pharmacokinetic data acquired during the VAL401, Phase II clinical trial that was concluded in Tbilisi, Georgia in 2017. VAL401 is a new formulation of the anti-psychotic drug, risperidone, enabling our oncology treatment. This analysis considers the clinical significance of the VAL401 results in comparison to previously reported data for conventional risperidone, providing a theoretical insight into the altered activity of the therapeutic.
Poor show from little man ss
dont you just love silent steve
Poor show from SS, eyes on site doing great job shame one way traffic only...
come on SS pull your finger out where is the RNS !!!!!!!!!!